These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7576913)

  • 21. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein.
    Shimizu N; Haraguchi Y; Takeuchi Y; Soda Y; Kanbe K; Hoshino H
    Virology; 1999 Jul; 259(2):324-33. PubMed ID: 10388657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.
    De Jong JJ; De Ronde A; Keulen W; Tersmette M; Goudsmit J
    J Virol; 1992 Nov; 66(11):6777-80. PubMed ID: 1404617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.
    Swart PJ; Kuipers ME; Smit C; Pauwels R; deBéthune MP; de Clercq E; Meijer DK; Huisman JG
    AIDS Res Hum Retroviruses; 1996 Jun; 12(9):769-75. PubMed ID: 8738428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
    Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
    Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.
    Meylan PR; Kornbluth RS; Zbinden I; Richman DD
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2910-6. PubMed ID: 7695283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41.
    Gordon LM; Waring AJ; Curtain CC; Kirkpatrick A; Leung C; Faull K; Mobley PW
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):677-86. PubMed ID: 7576927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops.
    Signoret N; de Jong J; Goudsmit J; Sattentau QJ
    AIDS Res Hum Retroviruses; 1997 Jan; 13(2):121-3. PubMed ID: 9007197
    [No Abstract]   [Full Text] [Related]  

  • 28. V3-mediated heparin neutralization of HIV type 1.
    Javaherian K; Khiroya R; Quinlan C; Boyd JG; Hanham KA
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1421-3. PubMed ID: 7888195
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.
    Langedijk JP; Zwart G; Goudsmit J; Meloen RH
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1153-62. PubMed ID: 8573370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death.
    Callebaut C; Jacotot E; Guichard G; Krust B; Rey-Cuille M; Cointe D; Benkirane N; Blanco J; Muller S; Briand J; Hovanessian AG
    Virology; 1996 Apr; 218(1):181-92. PubMed ID: 8615021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120.
    Kuipers ME; Huisman JG; Swart PJ; de Béthune MP; Pauwels R; Schuitemaker H; De Clercq E; Meijer DK
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):419-29. PubMed ID: 8605586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
    Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
    J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.
    Polzer S; Dittmar MT; Schmitz H; Meyer B; Müller H; Kräusslich HG; Schreiber M
    Glycobiology; 2001 Jan; 11(1):11-9. PubMed ID: 11181557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of structurally conservative amino acids of the HIV-1 protein gp120 V3 loop as promising targets for drug design by protein engineering approaches.
    Andrianov AM; Veresov VG
    Biochemistry (Mosc); 2006 Aug; 71(8):906-14. PubMed ID: 16978155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conserved V3 loop sequences and transmission of human immunodeficiency virus type 1.
    Shpaer EG; Delwart EL; Kuiken CL; Goudsmit J; Bachmann MH; Mullins JI
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1679-84. PubMed ID: 7888227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.
    Harvima IT; Harvima RJ; Nilsson G; Ivanoff L; Schwartz LB
    Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):711-8. PubMed ID: 8318003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.
    Sato H; Kato K; Takebe Y
    Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.